Apella Capital LLC Acquires 235,897 Shares of Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Apella Capital boosted its stake by 235,897 shares (a 2,359% increase) to own 245,897 shares—about 0.15% of Xeris, valued at roughly $1.93 million per its latest 13F filing.
• Analyst sentiment is positive overall with a consensus rating of "Moderate Buy" and a $10.80 target; several firms have recently upgraded the stock (e.g., Wall Street Zen to "strong-buy" and HC Wainwright reiterating a $10 buy).
• Insiders have been selling recently—75,835 shares (about $508k) sold last quarter, including a director sale of 10,834 shares at $5.54 and a 15,000-share sale at $8—while institutional ownership stands at 42.75%.

Apella Capital LLC increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 2,359.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 245,897 shares of the company's stock after acquiring an additional 235,897 shares during the quarter. Apella Capital LLC owned about 0.15% of Xeris Biopharma worth $1,930,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of XERS. Calamos Advisors LLC acquired a new stake in Xeris Biopharma during the 3rd quarter worth approximately $1,116,000. Voya Investment Management LLC boosted its position in Xeris Biopharma by 866.6% during the 3rd quarter. Voya Investment Management LLC now owns 400,079 shares of the company's stock worth $3,257,000 after buying an additional 358,689 shares during the period. Divisadero Street Capital Management LP acquired a new stake in Xeris Biopharma during the 3rd quarter worth approximately $3,308,000. Squarepoint Ops LLC boosted its position in Xeris Biopharma by 1,679.1% during the 2nd quarter. Squarepoint Ops LLC now owns 284,567 shares of the company's stock worth $1,329,000 after buying an additional 268,572 shares during the period. Finally, Granahan Investment Management LLC acquired a new stake in Xeris Biopharma during the 3rd quarter worth approximately $2,850,000. 42.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on XERS. Wall Street Zen upgraded shares of Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday, March 7th. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Weiss Ratings upgraded shares of Xeris Biopharma from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Wednesday, March 4th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Xeris Biopharma has a consensus rating of "Moderate Buy" and a consensus target price of $10.80.

Xeris Biopharma Price Performance

XERS stock opened at $5.87 on Wednesday. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -586.41 and a beta of 0.77. The company has a quick ratio of 1.57, a current ratio of 2.19 and a debt-to-equity ratio of 16.10. Xeris Biopharma Holdings, Inc. has a 12-month low of $3.81 and a 12-month high of $10.08. The company's fifty day simple moving average is $6.27 and its 200 day simple moving average is $7.26.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $85.81 million for the quarter, compared to analyst estimates of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. On average, analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Insider Activity

In other news, Director James Aloysius Brady sold 10,834 shares of Xeris Biopharma stock in a transaction on Monday, March 30th. The shares were sold at an average price of $5.54, for a total value of $60,020.36. Following the completion of the sale, the director owned 89,166 shares in the company, valued at $493,979.64. The trade was a 10.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $8.00, for a total transaction of $120,000.00. Following the completion of the sale, the insider owned 1,685,426 shares of the company's stock, valued at $13,483,408. This represents a 0.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 75,835 shares of company stock worth $508,194 in the last quarter. 4.56% of the stock is owned by corporate insiders.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.